LoginSignup
Halozyme logo

Halozyme

Stock
Stock
ISIN: US40637H1095
Ticker: HALO
US40637H1095
HALO

Price

Price

Frequently asked questions

What is Halozyme's market capitalization?

The market capitalization of Halozyme is $5.82B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Halozyme's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Halozyme is 15.14. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Halozyme?

Halozyme's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $3.022. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Halozyme's stock?

Currently, 9 analysts cover Halozyme's stock, with a consensus target price of $56.50. Analyst ratings provide insights into the stock's expected performance.

What is Halozyme's revenue over the trailing twelve months?

Over the trailing twelve months, Halozyme reported a revenue of $947.36M.

What is the EBITDA for Halozyme?

Halozyme's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $558.60M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Halozyme?

Halozyme has a free cash flow of $392.71M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Halozyme's stock?

The 5-year beta for Halozyme is 1.24. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Halozyme have, and what sector and industry does it belong to?

Halozyme employs approximately 373 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Halozyme's shares?

The free float of Halozyme is 125.85M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $5.82B

5Y beta

 1.24

EPS (TTM)

 $3.022

Free Float

 125.85M

P/E ratio (TTM)

 15.14

Revenue (TTM)

 $947.36M

EBITDA (TTM)

 $558.60M

Free Cashflow (TTM)

 $392.71M

Pricing

1D span
$44.76$46.39
52W span
$33.15$65.53

Analyst Ratings

The price target is $56.50 and the stock is covered by 9 analysts.

Buy

4

Hold

5

Sell

0

Information

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.

373

Biotechnology & Drugs

Health Care

Identifier

ISIN

US40637H1095

Primary Ticker

HALO

Knockouts

Join the conversation
Sign upLogin